Julian Baker and Felix Baker founded Baker Bros. Advisors in 2000. The fund invests only in the healthcare sector, with a large chunk of its portfolio being represented by biotechnology stocks and its latest 13F filing showed an equity portfolio worth $9.54 billion as of the end of June, compared to $9.48 billion a quarter earlier.
The equity portfolio also showed that the investor initiated positions in 10 companies during the second quarter, and since its top holdings weren’t changed significantly, in this article let’s take a closer look at Baker Bros.’ top new holdings added during the second quarter. Particularly, we are going to discuss Intellia Therapeutics Inc (NASDAQ:NTLA), Merus NV (NASDAQ:MRUS), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Minerva Neurosciences Inc (NASDAQ:NERV), and Syros Pharmaceuticals Inc (NASDAQ:SYRS).
We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).
Intellia Therapeutics Inc (NASDAQ:NTLA)
– Shares Owned by Baker Bros. Advisors (as of June 30): 1.06 million
– Value of Baker Bros. Advisors’ holding (as of June 30): $22.68 million
Julian and Felix Baker’s Baker Bros. Advisors added a stake in Intellia Therapeutics Inc (NASDAQ:NTLA), having acquired 1.06 million shares worth $22.68 million during the second quarter. Intellia Therapeutics Inc (NASDAQ:NTLA) is a small-cap biotech company that is engaged in genome editing. During the second quarter, its revenue increased by an annual 205% to $4.21 million, and it posted a loss of $6.9 million for the quarter, which is lower than the loss of $3.0 million posted a year earlier. The stock went public in May, having raised $170.5 million. However, its stock has slid by more than 41% since the IPO. Among the funds tracked by our team, eight funds have long positions in Intellia Therapeutics Inc (NASDAQ:NTLA) worth $88.81 million in aggregate as of the end of June.
Follow Intellia Therapeutics Inc. (NASDAQ:NTLA)
Follow Intellia Therapeutics Inc. (NASDAQ:NTLA)
Merus NV (NASDAQ:MRUS)
– Shares Owned by Baker Bros. Advisors (as of June 30): 1.12 million
– Value of Baker Bros. Advisors’ holding (as of June 30): $8.97 million
Julian and Felix Baker’s Baker Bros. Advisors added 1.12 million shares of Merus NV (NASDAQ:MRUS) to its equity portfolio during the second quarter $8.97 million during second quarter. The company reported revenue of 1.1 million euros ($1.24 million) and net loss of 0.40 euros per share ($0.45 per share) for second quarter, which compares with revenue of 1.2 million euros and a net loss of 1.25 euros per share posted for the same period of the last year. The company has cash and cash equivalents of €71.1 million ($80.37 million) as of the end of June. According to data tracked by our team, six funds held shares of Merus NV (NASDAQ:MRUS) with a total value of $16.41 million at the end of the second quarter.
On the next page, let’s look at Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Minerva Neurosciences Inc (NASDAQ:NERV), Syros Pharmaceuticals Inc (NASDAQ:SYRS).
